Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for STAB1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STAB1 ECD-Fc Recombinant Protein HEK293 expressed for native glycosylation. High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. Ideal for binding kinetics and ELISA. |
View STAB1 Products |
| Gene Delivery | STAB1 Promise-ORF / Lentivirus Full-length human STAB1 ORF for stable cell line generation. Essential for flow cytometry and cell-based internalization assays. |
View STAB1 Products |
| Benchmark Ab | Anti-STAB1 Recombinant Antibody (Bexmaralimab Biosimilar) Recombinant positive control antibody for functional blocking and benchmark assays. |
View STAB1 Products |
| Validator | STAB1 siRNA Set Target-specific knockdown verification in primary macrophages or lymphatic endothelial cells. |
View STAB1 Products |
| Related Target A | STAB2 (Stabilin-2) Homologous scavenger receptor. Critical counter-screening target to ensure drug selectivity and avoid systemic clearance toxicity. |
View STAB2 Products |
| Related Target B | SPARC Secreted Protein Acidic and Rich in Cysteine. Known physiological ligand of STAB1; essential for ligand-blocking assays. |
View SPARC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (Human vs. Cyno/Mouse) | Human, Mouse, and Cynomolgus STAB1 recombinant proteins available with strictly verified sequence identity. |
| STAB1/STAB2 subfamily counter-screening | High-purity STAB2 recombinant panel available to rule out off-target binding during lead optimization. |
| Lack of reliable positive controls | Sequence-verified clinical benchmark antibody (Bexmaralimab biosimilar) included in the catalog. |
| Conformation-dependent antibody screening | High-titer Lentivirus encoding full-length STAB1 for stable expression on target cells, preserving native multi-domain conformation. |
Live Stabilin-1 (STAB1) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Stabilin-1 (STAB1/CLEVER-1) therapeutics is intensifying, with major players shifting focus from traditional checkpoint inhibitors to macrophage-targeted immunotherapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the repolarization of tumor-associated macrophages (TAMs) from an immunosuppressive M2 phenotype to a pro-inflammatory M1 phenotype. STAB1 represents a premier target in this space due to its selective expression on immunosuppressive macrophages and lymphatic endothelial cells, avoiding systemic immune-related adverse events.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Faron Pharmaceuticals | Solid Tumors (Cutaneous Melanoma, Cholangiocarcinoma), Hematological Malignancies (MDS, AML) | Functional blocking assays (Need high-purity STAB1 ECD-Fc and ligand SPARC) |
| Bispecific / Multi-specific | Biotech Innovators | Refractory Solid Tumors | Dual-targeting validation (Need STAB1 and secondary checkpoint target proteins) |
| Cell Therapy / TAM Targeting | Academic & Clinical Institutes | Metastatic Cancers | Cell-based binding and internalization assays (Need STAB1 Lentivirus for stable cell lines) |